Zanini Andrea, Cherubino Francesca, Zampogna Elisabetta, Croce Stefania, Pignatti Patrizia, Spanevello Antonio
Division of Pneumology, IRCCS Rehabilitation Institute of Tradate, Salvatore Maugeri Foundation (IRCCS), Tradate, Italy.
Allergy and Immunology Unit, Salvatore Maugeri Foundation (IRCCS), Pavia, Italy.
Int J Chron Obstruct Pulmon Dis. 2015 Jun 17;10:1155-61. doi: 10.2147/COPD.S80992. eCollection 2015.
Bronchial hyperresponsiveness (BHR), sputum eosinophilia, and bronchial reversibility are often thought to be a hallmark of asthma, yet it has been shown to occur in COPD as well.
To evaluate the relationship between BHR, lung function, and airway inflammation in COPD patients.
Thirty-one, steroid-free patients with stable, mild and moderate COPD were studied. The following tests were carried out: baseline lung function, reversibility, provocative dose of methacholine causing a 20% fall in forced expiratory volume in 1 second, a COPD symptom score, and sputum induction.
Twenty-nine patients completed the procedures. About 41.4% had BHR, 31.0% had increased sputum eosinophils, and 37.9% had bronchial reversibility. Some of the patients had only one of these characteristics while others had two or the three of them. Patients with BHR had higher sputum eosinophils than patients without BHR (P=0.046) and those with sputum eosinophils ≥3% had more exacerbations in the previous year and a higher COPD symptom score than patients with sputum eosinophils <3% (P=0.019 and P=0.031, respectively). In patients with BHR, the cumulative dose of methacholine was negatively related to the symptom score and the number of exacerbations in the previous year. When patients with bronchial reversibility were considered, bronchodilation was positively related to sputum eosinophils.
Our study showed that BHR, sputum eosinophilia, and bronchial reversibility were not clustered in one single phenotype of COPD but could be present alone or together. Of interest, BHR and airway eosinophilia were associated with clinical data in terms of exacerbations and symptoms. Further investigation is needed to clarify this topic.
支气管高反应性(BHR)、痰液嗜酸性粒细胞增多和支气管可逆性常被认为是哮喘的标志,但研究表明其也会出现在慢性阻塞性肺疾病(COPD)中。
评估COPD患者中BHR、肺功能和气道炎症之间的关系。
对31例稳定期轻、中度COPD且未使用类固醇药物的患者进行研究。进行了以下检查:基线肺功能、可逆性、使第1秒用力呼气容积下降20%的乙酰甲胆碱激发剂量、COPD症状评分以及痰液诱导检查。
29例患者完成了各项检查。约41.4%的患者有BHR,31.0%的患者痰液嗜酸性粒细胞增多,37.9%的患者有支气管可逆性。部分患者仅具备其中一项特征,而其他患者具备两项或三项特征。有BHR的患者痰液嗜酸性粒细胞高于无BHR的患者(P = 0.046),痰液嗜酸性粒细胞≥3%的患者上一年急性加重次数更多,且COPD症状评分高于痰液嗜酸性粒细胞<3%的患者(分别为P = 0.019和P = 0.031)。在有BHR的患者中,乙酰甲胆碱累积剂量与症状评分及上一年急性加重次数呈负相关。当考虑有支气管可逆性的患者时,支气管扩张与痰液嗜酸性粒细胞呈正相关。
我们的研究表明,BHR、痰液嗜酸性粒细胞增多和支气管可逆性并非集中于COPD的单一表型,而是可能单独或共同存在。有趣的是,BHR和气道嗜酸性粒细胞增多在急性加重和症状方面与临床数据相关。需要进一步研究以阐明该问题。